The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan

International Diabetes Federation (IDF) 2017. IDF Diabetes Atlas 8th ed. http://www.diabetesatlas.org/resources/2017-atlas.html . Accessed 22 Jan 2018.

Ajlouni K, Khader YS, Batieha A, Ajlouni H, El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complicat. 2008;22:317–24. https://doi.org/10.1016/j.jdiacomp.2007.01.004 .

Khader Y, Batieha A, Ajlouni H, El-Khateeb M, Ajlouni K. Obesity in Jordan: prevalence, associated factors, comorbidities, and change in prevalence over ten years. Metab Syndr Relat Disord. 2008;6(2):113–20. https://doi.org/10.1089/met.2007.0030 .

World Health Organization. http://www.who.int/topics/obesity/en/ . Accessed 22 Jan 2018.

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14. https://doi.org/10.1002/dmrr.2239 .

Callaghan BC, Cheng HT, Stables CL, Andrea L, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34. https://doi.org/10.1016/s1474-4422(12)70065-0 .

Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diabetes Rep. 2012;12:376–83. https://doi.org/10.1007/s11892-012-0278-3 .

Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15:508–514. https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L.

Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag. 2007;3:65–76.

Boulton AJ, Vinik AI, Arezzo JC, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62. https://doi.org/10.2337/diacare.28.4.956 .

Palumbo PJ, Melton LJ. Peripheral vascular disease and diabetes. Diabetes Am. 1995;2:401–8.

Rathur HM, Boulton AJ. The diabetic foot. Clin Dermatol. 2007;25:109–20. https://doi.org/10.1016/j.clindermatol.2006.09.015 .

Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB. Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otol Neurotol. 2010;31:1445–50. https://doi.org/10.1097/mao.0b013e3181f2f035 .

Niranjan Y, Santwani MA, Baghel MS. Quality of life consequences in diabetic polyneuropathy. Glob J Res Med Plants Indig Med. 2012;1:295–300.

Jordan statistical yearbook 2016. Department of Statistics.

American Diabetes Association. Standards of medical care in diabetes. Diabetes care. 2014;37(Supp1):S14–80. https://doi.org/10.2337/dc14-s014 .

Scale DE. Michigan Diabetes Research and Training Center. Online. https://diabetesresearch.med.umich.edu/Tools_SurveyInstruments.php . Accessed 22 Jan 2018.

Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabetes Med. 2012;29:937–44. https://doi.org/10.1111/j.1464-5491.2012.03644.x .

Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108:477–81. https://doi.org/10.1016/j.clineuro.2005.08.003 .

Al-Geffari M. Comparison of different screening tests for diagnosis of diabetic peripheral neuropathy in Primary Health Care setting. Int J Health Sci. 2012;6:127–34. https://doi.org/10.12816/0005988 .

Tabatabaei-Malazy O, Mohajeri-Tehrani MR, Madani SP, Heshmat R, Larijani B. The prevalence of diabetic peripheral neuropathy and related factors. Iran J Public Health. 2011;40:55–62. https://doi.org/10.1097/qad.0b013e328345889d .

Al-Kaabi JM, Al-Maskari F, Zoubeidi T, Abdulle A, Shah SM, Cragg P, Afandi B, Souid A. Prevalence and determinants of peripheral neuropathy in patients with type 2 diabetes attending a tertiary care center in the United Arab Emirates. J Diabetes Metab. 2014;5:346–53. https://doi.org/10.4172/2155-6156.1000346 .

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 2014;5:714–21. https://doi.org/10.1111/jdi.12223 .

Elrefai JM. Prevalence of neuropathy in the diabetic foot. Neurosciences. 2009;14:163–6.

Al-Sarihin K, Althwabia I, Khaled MB, Haddad F. Prevalence of peripheral neuropathy among patients with diabetes mellitus at King Hussein Hospital, Amman, Jordan. RMJ. 2013;38:92–6.

Pop-Busui R, Lu J, Lopes N, Jones TL. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D Cohort. J Peripher Nerv Syst. 2009;14:1–3. https://doi.org/10.1111/j.1529-8027.2009.00200.x .

Liu F, Bao Y, Hu R, Zhang X, Li H, Zhu D, Li Y, Yan L, Li Y, Lu J, Li Q, Zhao Z, Ji Q, Jia W. Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicenter survey in 12 city hospitals of China. Diabetes Metab Res Rev. 2010;26:481–9. https://doi.org/10.1002/dmrr.1107 .

Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012;4:21–8. https://doi.org/10.1186/1758-5996-4-21 .

Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, Cha BY. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med. 2012;29:e290–6. https://doi.org/10.1111/j.1464-5491.2012.03697.x .

Rosson GD, Dellon AL. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:1925–7. https://doi.org/10.1056/nejmoa032782 .

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70. https://doi.org/10.2337/dc06-1216 .

Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH. Showing neuropathy is related to increased mortality in diabetic patients—a survival analysis using an accelerated failure time model. J Clin Epidemiol. 2000;53:519–23. https://doi.org/10.1016/s0895-4356(99)00170-5 .

Hsu WC, Chiu SH, Yen AF, Chen LS, Fann CY, Liao CS, Chen HH. Somatic neuropathy is an independent predictor of all-and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol. 2012;19:1192–8. https://doi.org/10.1111/j.1468-1331.2011.03659.x .

Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol. 2005;5:24–8. https://doi.org/10.1186/1471-2377-5-24 .

Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Ann Saudi Med. 2007;27:25–31. https://doi.org/10.4103/0256-4947.51536 .

Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013;74:397–403. https://doi.org/10.1002/ana.23986 .

Smith AG, Singleton JR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complicat. 2013;27:436–42. https://doi.org/10.1016/j.jdiacomp.2013.04.003 .

Thomas PK, Ward JD, Watkins PJ. Diabetic neuropathy: complications of diabetes. London: Edward Arnold publications; 1982. p. 109–36.

Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51–63. https://doi.org/10.1186/1741-7015-12-51 .

Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995;58:625–8. https://doi.org/10.1136/jnnp.58.5.625 .

Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, Sharma N, Wright DE. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complicat. 2012;26:424–9. https://doi.org/10.1016/j.jdiacomp.2012.05.007 .

Paul D, Loprinzi A, Kathy K, Hager B, Pradeep Y, Ramulu C. Physical activity, glycemic control, and diabetic peripheral neuropathy: a national sample. J Diabetes Complicat. 2014;28:17–21. https://doi.org/10.1016/j.jdiacomp.2013.08.008 .

Loprinzi PD, Ramulu PY. Objectively measured physical activity and inflammatory markers among US adults with diabetes: implications for attenuating disease progression. Mayo Clin Proc. 2013;88:942–51. https://doi.org/10.1016/j.mayocp.2013.05.015 .

Diabetes Control and Complication Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8. https://doi.org/10.7326/0003-4819-122-8-199504150-00001 .

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67. https://doi.org/10.1001/jama.290.16.2159 .

Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340–4. https://doi.org/10.2337/diacare.29.02.06.dc05-1549 .

Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14:1–5. https://doi.org/10.1007/s11892-014-0528-7 .

Dziemidok P, Szczesniak G, Kostrzewa-Zablocka E, Paprzycki P, Korzon-Burakowska A. Current glycaemic control has no impact on the advancement of diabetic neuropathy. Ann Agric Environ Med. 2012;19:742–5.

Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF, Wu G, Jin Y, Wang XH. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6:1–7. https://doi.org/10.1186/1758-5996-6-139 .

Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) cohort. Diabetes Care. 2013;36:3208–15. https://doi.org/10.2337/dc13-0012 .

Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and UK. Prim Care Diabetes. 2014;8:250–5. https://doi.org/10.1016/j.pcd.2014.01.011 .

Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54:2179–87. https://doi.org/10.2337/diabetes.54.7.2179 .

Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26:611–7. https://doi.org/10.1161/01.atv.0000201938.78044.7 .

Savage S, Estacio RO, Jeffers B, Schrier RW. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Proc Assoc Am Physicians. 1997;109:181–9.